Nasdaq halts Chronimed after miscounting:
This article was originally published in Clinica
Executive Summary
The US Nasdaq stock market halted trading in Chronimed shares on Thursday after the distribution company announced that it had been overstating sales and earnings for the past two years through inadvertent double counting in its StatScript subsidiary.